Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02367105 · ClinicalTrials.gov registry record · Phase 3
Lifestyle Intervention and Testosterone Replacement in Obese Seniors
A Phase 3 study, sponsored by VA Office of Research and Development.
- Completed
- Registry status
- Phase 3
- Development phase
- 83
- Enrollment target
NCT02367105: Completed Phase 3 study, sponsored by VA Office of Research and Development.
NCT02367105 is a Phase 3 study that has completed, run by VA Office of Research and Development. The registered enrollment target is 83 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02367105, a Phase 3 study, has completed, sponsored by VA Office of Research and Development.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 83 participants
- Enrollment target
Study Summary
The prevalence of obesity in Veterans is greater than in the general population, and even more so among users of the VA Health Care System. In addition, the population of obese older Veterans is rapidly increasing as more baby boomers become senior citizens. In older Veterans, obesity exacerbates the age- related decline in physical function and causes frailty which predisposes to admission to a VA chronic care facility. However, the optimal clinical approach to obesity in older adults is controversial because of the concern that weight loss therapy could be harmful by aggravating the age-related loss of muscle mass and bone mass. In fact, the MOVE (Managing Overweight/Obese Veterans) program does not have any guidelines for eligible Veterans if they are 70 or older. It is possible that the addition of testosterone replacement to lifestyle therapy will preserve muscle mass and bone mass and reverse frailty in obese older Veterans and thus prevent their loss of independence and decrease demand for VA health care services.
Interventions
- DRUG Placebo
- DRUG Testosterone
- OTHER Lifestyle Therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 83 participants |
| Start Date | 2015-02-01 |
| Est. Completion | 2019-12-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02367105
The ClinicalTrials.gov registry entry for NCT02367105 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 83 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is VA Office of Research and Development, which has 1,668 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02367105 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02367105 about?
NCT02367105 is a clinical study titled "Lifestyle Intervention and Testosterone Replacement in Obese Seniors". The prevalence of obesity in Veterans is greater than in the general population, and even more so among users of the VA Health Care System. In addition, the population of obese older Veterans is rapidly increasing as more baby boomers become senior citizens. In older Veterans, obesity exacerbates th...
What is the current status of trial NCT02367105?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 83 participants. The study started on 2015-02-01. Estimated completion is 2019-12-31.
What interventions are being tested in trial NCT02367105?
The interventions under investigation include: Placebo (DRUG), Testosterone (DRUG), Lifestyle Therapy (OTHER).
Who is sponsoring clinical trial NCT02367105?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.